While cessation of GLP-1 RA treatment is associated with marked weight regain, whether repeated GLP-1 RAs treatment and subsequent weight regain increases the risk for sarcopenia or sarcopenic obesity remains unknown. This evidence concerns the gene GLP1R and sarcopenia.